Exploration on the Interaction Ability of Antitumor Compound Bis-[2,6-difluoro-N-(hydroxyl-<κ>O)benzamidato-<κ>O]dibutylitin(IV) with Human Peroxisome Proliferator-Activated Receptor hPPARγ

<div>DARTS detection via SDS-PAGE. Band 1 was pure hPPARγ protein without incubation with DBDF2,6T or proteolysis; bands 2 and 3 were hPPARγ protein incubated with 0.5 × 10−2 mol/L and 1.0 × 10−2 mol/L DBDF2,6T, respectively, and without proteolysis; bands 4 to 8 were hPPARγ protein incubated with DMSO and different concentrations of DBDF2,6T (5→8: 0.5 × 10−2 mol/L, 0.5 × 10−3 mol/L, 0.5 × 10−4 mol/L, and 0.5 × 10−5 mol/L), respectively, and with proteolysis.</div>

Bioinorganic Chemistry and Applications

fig6

Figure 6

Figure 6: Exploration on the Interaction Ability of Antitumor Compound Bis-[2,6-difluoro-N-(hydroxyl-<κ>O)benzamidato-<κ>O]dibutylitin(IV) with Human Peroxisome Proliferator-Activated Receptor hPPARγ

Figure 6 | Exploration on the Interaction Ability of Antitumor Compound Bis-[2,6-difluoro-N-(hydroxyl-O)benzamidato-O]dibutylitin(IV) with Human Peroxisome Proliferator-Activated Receptor hPPARγ 